-
[show abstract]
[hide abstract]
ABSTRACT: To evaluate the protective rate and the variation of HFRS-IgG on hemorrhagical fever with renal syndrome (HFRS) vaccine.
Cluster, random sampling and cross-sectional study were used to assess the protective rate of HFRS vaccination. Level of HFRS-IgG was detected with ELISA in epidemic and non-epidemic areas of HFRS.
Curve equation was obtained as Yprotective rate=(0.863+0.283/Xvaccination term)×100% by protective rate with vaccination term. Protective rates showed a reducing trend, 90% after 7-8 years of vaccination, 88% after 10 years, and 94% on average. Absorbance (A) value of HFRS-IgG was 4 times higher in persons with vaccination than those without, in the epidemic area. Higher antibody level could be obtained after primary vaccination, but the level of antibody had a 50% reduction after 5-10 years of vaccination, and a 60% reduction after 10 years of vaccination.
HFRS antibody had a 50% reduction after 5-10 years of vaccination. The protective rate of HFRS vaccination had a 90% loss, after 7-8 years of vaccination. Booster dose was necessary after 7 years of vaccination.
Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi 03/2012; 33(3):309-12.
-
Jing-Jun Wang,
Yuan Zheng,
Liang Sun,
Li Wang,
Peng-Bo Yu,
Hong-Lei Li,
Xiao-Ping Tian, Jian-Hua Dong,
Lei Zhang,
Jing Xu,
Wei Shi,
Tao-Yan Ma
[show abstract]
[hide abstract]
ABSTRACT: Lung cancer is the second most common human malignant disease and the leading cause of cancer-related mortality worldwide. The effect of CYP1A1 IleVal polymorphism on susceptibility to lung cancer has been researched extensively over the last two decades. However, controversial results were obtained. To provide a more robust estimate of the effect, a meta-analysis was carried out. We systematically searched the PubMed database for studies published before August 2010, without language restriction. On the basis of our search criteria, a total of 32 studies (5126 patients and 6974 controls) were included in the meta-analysis. Overall, CYP1A1 IleVal polymorphism is associated with lung cancer risk (GG vs. AG+AA: odds ratio=1.61, 95% confidence interval: 1.19-2.17; GG vs. AA: odds ratio=1.70, 95% confidence interval: 1.23-2.35). Ethnic subgroup analyses showed that a significant association was found in Asians, but not in Africans, Caucasians, or other populations. In subgroup analyses by histology, the result is not reliable. In conclusion, this meta-analysis suggests that the CYP1A1 IleVal polymorphism might play a modest role in susceptibility to lung cancer, especially in Asians.
European journal of cancer prevention: the official journal of the European Cancer Prevention Organisation (ECP) 11/2011; 20(6):445-52. · 2.21 Impact Factor
-
[show abstract]
[hide abstract]
ABSTRACT: Colorectal cancer constitutes a significant proportion of the global burden of cancer morbidity and mortality. A number of studies have been conducted to explore whether TP53 codon 72 polymorphism is associated with colorectal cancer susceptibility. However, controversial results were obtained. In order to derive a more precise estimation of the relationship, we systematically searched Medline, Google scholar, and Ovid database for studies reported before May 2010. A total of 3603 colorectal cancer cases and 5524 controls were included. TP53 codon 72 polymorphism was not associated with colorectal cancer risk in all genetic models (for dominant model: OR = 0.99, 95% CI: 0.86-1.15; for recessive model: OR = 1.00, 95% CI: 0.81-1.23; for Arg/Pro vs. Arg/Arg: OR = 1.00, 95% CI: 0.87-1.15; for Pro/Pro vs. Arg/Arg: OR = 0.97, 95% CI: 0.76-1.25). In the subgroup analyses by ethnic groups and sources of controls, no significant associations were found in all models. Taken together, this meta-analysis suggested that the biologically usefulness of TP53 codon 72 polymorphism as a selection marker in colorectal cancer susceptibility may be very limited.
Molecular Biology Reports 12/2010; 38(8):4847-53. · 2.93 Impact Factor
-
Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi 04/2009; 30(3):310-1.
